B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression - Wikidata - awgldk - TriplyDB

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

http://www.wikidata.org/entity/Q33934897

about

TERT promoter mutations in thyroid cancer Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Metastatic mechanisms in follicular cell-derived thyroid cancer Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations Oxidative stress: a new risk factor for thyroid cancer Harnessing the complexity of gene expression data from cancer: from single gene to structural pathway methods TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation.S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging.Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment Molecular pathogenesis and mechanisms of thyroid cancer Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?Association of the ATM gene polymorphisms with papillary thyroid cancer.Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study.The thrombospondins.Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis.BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF Epigenetics modifications and therapeutic prospects in human thyroid cancer.Poorly differentiated thyroid carcinoma: an incubating entity.Anaplastic thyroid carcinoma SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.Targeted Therapy for MAPK Alterations in Pediatric Gliomas.BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma.Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric andTeen Patients Allows Identifying Two Main Classes of Biological ProcessesInvolved and New Potential Therapeutic Targets FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.

P2860

Q26770808-2EF429FD-73F1-4207-9E61-55567E7F2DCE Q26824518-A71FC471-2349-4E0E-AD0D-DB3C3506ABE0 Q26853261-BC699E30-555D-4CC7-8976-12334367A591 Q27005646-8FF044EE-B34E-42F7-9D7F-B5DEE0D7E7BB Q27027491-DA35E640-F5A0-4802-A3C8-2A9409846678 Q28388902-C8B1BA48-3A0D-4268-A01D-537FB0886529 Q30580995-4EF3293A-1D71-4583-99FF-985358FDECA2 Q33682388-436F576D-6A29-4B44-BD50-4DF1458EEBA8 Q33864242-F541A45E-C366-45BD-9E50-AAF4FB7CF551 Q34027466-40F6B8DB-39CA-429A-AFF2-4291120E77C8 Q34100838-54C80CF4-D13B-4A96-966E-8044C7370557 Q34137706-F0BB9DFE-A75D-4069-B821-35D35AE5A20F Q34329018-E9081D11-93A6-4937-A465-6237B670E292 Q34776121-66238166-F212-49A4-83C9-9D1C354FB79B Q34781888-FF0771E1-A49C-440B-84F8-47EAEBF062DC Q34909764-177F1AAD-4B13-4322-AB63-6A3D64E22DAA Q35091350-802B3351-1F01-4FAA-9ABB-89EA00D5EEE7 Q35230013-3414A749-F421-412D-9510-3A827F89FA24 Q35554680-0DD90AB8-940A-4BDF-BBE6-FE43D119DFA1 Q35578577-CA0D48D2-D21D-4949-B313-0AD268504E90 Q35623044-3E6FE6C8-A459-4914-9778-BAEA1BA77153 Q35744562-6589E3B9-1424-48FF-B8FC-0246AD2AAAA6 Q35751013-9601E2B2-D6B3-485A-A15F-B3AE7CA3C505 Q35804895-3B177204-240C-4C38-B936-C0171872217D Q35857363-C8A960B4-0D89-4A3B-8759-31F1F023F83F Q35914464-F4C378E4-C736-4339-B20D-C6CDD9630D3B Q35971504-EA40807C-F2E1-4E77-8D71-38CA72AD5FDE Q36050222-D7237262-09C0-43DB-823B-565C90589030 Q36075843-93B40E8D-1E1F-4086-93C5-670ED87581C8 Q36118305-D687D7DB-EE84-451D-8385-9E1102B88B4A Q36233325-0676F13B-F9AC-4A43-A958-FE2995E4234C Q36413759-2AC7590D-0EE8-4241-B13F-145968B54424 Q36431628-BA31607B-B306-407B-B47F-0BE7B3EE6FD7 Q36586178-95C61449-7CA3-45D4-9845-8F4DFA55C422 Q36601451-D94EF445-95D1-45FE-926D-D16AA0E1B5E1 Q36618887-B48AD070-841C-475C-B689-0C189C3E2E5F Q36658489-EEF5562A-0784-4721-9269-962F510A2260 Q36799818-F76DE989-6250-4C93-8719-B78970BBFE18 Q36905856-76620635-12B4-494A-9C23-6FDD8B5283E3 Q36917756-316F5A45-DEA7-43FC-8BFD-B1E0D709D9EF

P2860

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

http://www.wikidata.org/entity/Q33934897

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

@ast

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

@en

type

label

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

@ast

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

@en

altLabel

B-RafV600E and thrombospondin-1 promote thyroid cancer progression

@en

prefLabel

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

@ast

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

@en

P1433

Q33934897-6BF6893E-8A43-4358-B503-618B13DB0BA5

P1476

Q33934897-87BC7E72-355C-4A9E-AF86-2070A9DC845F

P2093

Q33934897-06F76037-3ABC-4282-9383-4F51BC85F5BD

Q33934897-4EE518C2-4B8C-48DC-B090-177E673948E0

Q33934897-72DDB56F-563C-4C81-8368-85B6585C01FA

Q33934897-754C7845-57B4-44A0-BB52-DCD5B71E1B1A

Q33934897-85C6AE22-7C57-4E2C-A5CE-8F996528319C

Q33934897-9586AA81-EBE6-4868-A422-4EDA68B05C1B

Q33934897-9689FFC7-4CF8-4184-A43C-BCEE1025E32C

Q33934897-998926CA-3630-4861-ACAE-11ADC36D7287

Q33934897-A97A3D2C-19BE-45B7-BBBC-E23873C517D9

Q33934897-B5313879-EFDB-4F29-BA39-8B41E85742F6

P2860

Q33934897-03104A74-E1D9-4024-8FBD-727F928CE209

Q33934897-048A599A-E39A-40D9-9408-55A38264D5D7

Q33934897-103FE910-08B1-4FAE-98A2-7E5B715C44EA

Q33934897-1474D8FC-44D0-4BDF-97A8-91F91F91FF19

Q33934897-1475C6B7-005D-4F41-91D0-24A8244E6DF2

Q33934897-17A42917-30D9-4275-8F5B-C5720F397BBB

Q33934897-327B882C-7648-4B29-B570-A39F7B012C34

Q33934897-34041718-ABBB-445B-A5DD-E19AD10E80CF

Q33934897-3EF9BDE2-865D-4EEB-9DF0-76EE3C7F0B98

Q33934897-44034C1D-631F-4946-A14C-171F966C8FEB

P304

Q33934897-7574295F-F16F-4E80-8032-B4A0F5C7AF4C

P31

Q33934897-D1DAB6C6-9360-46DB-BFE3-5018B53023EA

P356

Q33934897-A19963A1-95CB-4C47-A410-2497E718148B

P407

Q33934897-73B05B3F-CBB4-4BE7-891F-59C2163FED33

P433

Q33934897-BB968189-FF60-4428-91D4-D215E963F2DD

P478

Q33934897-2434C887-1AC9-41CF-852E-1102BC72E6A9

P50

Q33934897-852CBB6F-0728-439D-8622-C910B0AD3DFC

Q33934897-8D7B2671-7165-479A-97B8-7A128E76D203

Q33934897-98D3172D-455E-4EA5-AB44-E816435263A7

Q33934897-E5BE3C01-DBDA-44F8-974E-33A3126DB101

P577

Q33934897-4052A142-1975-4AA3-ADE2-A24802778B7E

P5875

Q33934897-6E84C642-AC5C-4098-B199-AD2E98BAA4C7

P698

Q33934897-E9E7FB9F-587F-48DD-920A-08EE203D2E3A

P932

Q33934897-67C74200-1FBA-4399-90C3-D6691978EE34

P356

PNAS.1004934107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

@en

P2093

Alessandro Porrello

http://www.w3.org/2001/XMLSchema#string

Alfredo Pontecorvi

http://www.w3.org/2001/XMLSchema#string

Carmelo Nucera

http://www.w3.org/2001/XMLSchema#string

Carmen Priolo

http://www.w3.org/2001/XMLSchema#string

Damien Gerald

http://www.w3.org/2001/XMLSchema#string

Efisio Puxeddu

http://www.w3.org/2001/XMLSchema#string

Jack Lawler

http://www.w3.org/2001/XMLSchema#string

Laura E Benjamin

http://www.w3.org/2001/XMLSchema#string

Matthew A Nehs

http://www.w3.org/2001/XMLSchema#string

Michal Mekel

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Integrins: bidirectional, allosteric signaling machines

Mutations of the BRAF gene in human cancer

The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity

Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.

BRAF(V600E) mutation and the biology of papillary thyroid cancer.

P304

10649-10654

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1004934107

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Barbara Jarząb

Thomas Giordano

Stephen P. Finn

Zeus Andrea Antonello

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44626109

http://www.w3.org/2001/XMLSchema#string

P698

20498063

http://www.w3.org/2001/XMLSchema#string

P932

2890809

http://www.w3.org/2001/XMLSchema#string